$4.70
0.21% yesterday
Nasdaq, Feb 28, 04:46 pm CET
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Vanda Pharmaceuticals Inc. Stock price

$4.71
+0.26 5.84% 1M
-0.78 14.21% 6M
-0.08 1.67% YTD
+0.15 3.29% 1Y
-6.65 58.54% 3Y
-6.61 58.39% 5Y
-6.33 57.34% 10Y
Nasdaq, Closing price Wed, Feb 26 2025
+0.25 5.61%
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Key metrics

Market capitalization $274.09m
Enterprise Value $-88.19m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 5.43
EV/Sales (TTM) EV/Sales -0.44
P/S ratio (TTM) P/S ratio 1.38
P/B ratio (TTM) P/B ratio 0.51
Revenue growth (TTM) Revenue growth 3.18%
Revenue (TTM) Revenue $198.77m
EBIT (operating result TTM) EBIT $-40.66m
Free Cash Flow (TTM) Free Cash Flow $-16.25m
Cash position $374.64m
EPS (TTM) EPS $-0.33
P/E forward negative
P/S forward 1.23
EV/Sales forward negative
Short interest 8.25%
Show more

Is Vanda Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Vanda Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

Buy
67%
Hold
33%

Financial data from Vanda Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
199 199
3% 3%
100%
- Direct Costs 19 19
10% 10%
9%
180 180
3% 3%
91%
- Selling and Administrative Expenses 138 138
26% 26%
70%
- Research and Development Expense 74 74
3% 3%
37%
-33 -33
197% 197%
-16%
- Depreciation and Amortization 8.13 8.13
170% 170%
4%
EBIT (Operating Income) EBIT -41 -41
191% 191%
-20%
Net Profit -19 -19
853% 853%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about Vanda Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vanda Pharmaceuticals Inc. Stock News

Neutral
PRNewsWire
4 days ago
WASHINGTON , Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" in Molecular Therapy Nucleic Acids1, a Cell Press partner journal, that describes the development of a novel antisense oligonucleotide (ASO) therapeutic, VCA-894A, ...
Neutral
Seeking Alpha
15 days ago
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & Chairman Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Andrew Tsai - Jefferies Operator Hello, and thank you for standing by.
Neutral
PRNewsWire
15 days ago
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total revenues of $198.8 million, +3% compared to full year 2023 Full year 2025 revenue expected to grow to $210 to $250 million Psychiatry portfolio revenue expected to grow to greater than $750 million in 2030 Fanapt® MAA for bipolar I d...
More Vanda Pharmaceuticals Inc. News

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Head office United States
CEO Mihael Polymeropoulos
Employees 368
Founded 2002
Website www.vandapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today